Please review the important safety information below for intended use, limitations of use, risks, warnings, precautions, possible side effects, use in specific populations, and medication interactions for the prescription treatments advertised by Better Health Labs, Inc. d/b/a Measured ("Measured"). This information is not a substitute for medical advice, diagnosis, or treatment. Patients should consult their licensed healthcare provider regarding whether any treatment is appropriate for their individual medical history, goals, and current medications.

In the event of a medical emergency, call 911 or go to the nearest emergency room immediately. Patients should promptly report side effects, unexpected reactions, or other safety concerns to their prescribing provider and dispensing pharmacy. Suspected adverse reactions may also be reported to the U.S. Food and Drug Administration through MedWatch at 1-800-FDA-1088 or through the FDA’s online reporting portal:
https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program

About Measured’s Services

Measured is a technology and administrative services platform that facilitates access to telehealth consultations with licensed healthcare providers. Measured does not itself practice medicine, provide medical advice, manufacture medications, compound medications, or dispense medications. Any prescription is issued solely at the independent clinical judgment of a licensed healthcare provider, if the provider determines that treatment is medically appropriate for the patient. If a prescription is written, it may be sent to a licensed pharmacy selected by the patient or otherwise directed in connection with the provider’s care plan and applicable pharmacy processes.

Prescription treatment is not guaranteed. Not every patient is a candidate for every treatment. Eligibility, prescribing decisions, dosage, treatment duration, refill decisions, and ongoing monitoring are determined by the treating provider based on clinical appropriateness and applicable law. Product availability may vary by state, patient profile, pharmacy supply, and other factors.

Advertisements and website content made available by Measured are for informational and marketing purposes only. Images may depict sample packaging, stock photography, or illustrative representations. Actual medication packaging, labeling, dosage form, concentration, device configuration, and instructions may differ from what is shown.

Prescription Medications Generally

All prescription medications carry risks, including the risk of serious side effects, allergic reactions, drug-drug interactions, contraindications, and adverse outcomes in certain patient populations. Patients should carefully review all prescribing information, medication guides, pharmacy labeling, and instructions for use that accompany their prescribed medication. Patients should tell their provider about all medical conditions, allergies, prior adverse drug reactions, pregnancy or breastfeeding status, and all prescription drugs, over-the-counter medications, supplements, and herbal products they use.

Patients should not start, stop, substitute, or combine prescription treatments without guidance from a licensed healthcare provider. Prescription medications should be used only as prescribed and should never be shared with another person.

FDA-Approved Branded Products vs. Compounded Medications

Measured may facilitate access to certain FDA-approved prescription medications and, in some cases, compounded medications prescribed by a licensed healthcare provider. FDA-approved medications are reviewed by the FDA for safety, effectiveness, and quality for their approved uses. Compounded medications are different. Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. When prescribed, compounded medications may be used in patient-specific circumstances as determined by the treating provider and dispensing pharmacy, subject to applicable law and pharmacy practice requirements.

Patients should not assume that compounded medications are the same as FDA-approved branded products. The active ingredient, inactive ingredients, concentration, dosage form, route of administration, packaging, storage requirements, and pharmacy labeling may differ. FDA-approved alternatives may be available. Additional information regarding human drug compounding is available from the FDA at:
https://www.fda.gov/drugs/human-drug-compounding

Official Prescribing Information and FDA Resources

Patients are encouraged to review the full official prescribing information for FDA-approved medications discussed on this page. Those materials include detailed information regarding indications, contraindications, boxed warnings, warnings and precautions, adverse reactions, administration instructions, and other prescribing details.

FDA MedWatch Safety Reporting
https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program

Wegovy® Prescribing Information
https://www.novo-pi.com/wegovy.pdf

Ozempic® Prescribing Information
https://www.novo-pi.com/ozempic.pdf

Mounjaro® Prescribing Information
https://pi.lilly.com/us/mounjaro-uspi.pdf

Zepbound® Prescribing Information
https://pi.lilly.com/us/zepbound-uspi.pdf

Boxed Warning for Semaglutide- and Tirzepatide-Containing Treatments

Certain medications referenced on this page contain semaglutide or tirzepatide and carry boxed warning language regarding the risk of thyroid C-cell tumors. These medications should not be used in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether these medications cause thyroid C-cell tumors, including MTC, in humans.

Patients should promptly seek medical evaluation if they develop a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. Patients should review the full manufacturer labeling for the specific medication prescribed to them and discuss all risks, contraindications, warnings, and precautions with their licensed healthcare provider.

GLP-1 and Related Weight Loss / Metabolic Treatments

Several of the treatments referenced on this page contain semaglutide or tirzepatide, or otherwise relate to the GLP-1 treatment category. These medications may carry significant warnings and precautions, including the risk of thyroid C-cell tumors reflected in boxed warnings for certain FDA-approved semaglutide and tirzepatide products. These medications should not be used in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Patients should promptly seek medical evaluation if they develop a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath.

Semaglutide- and tirzepatide-containing therapies may also be associated with gastrointestinal side effects and serious risks including, where applicable, nausea, vomiting, diarrhea, constipation, abdominal pain, delayed gastric emptying, dehydration, kidney injury, gallbladder problems, pancreatitis, hypoglycemia when used with insulin or insulin secretagogues, worsening diabetic retinopathy in certain patients, heart rate increase in some cases, pulmonary aspiration risk during general anesthesia or deep sedation in some settings, and serious hypersensitivity reactions. These treatments may not be appropriate for all patients. Patients should discuss all risks, warnings, and precautions with their prescribing provider before starting therapy and during ongoing treatment.

Unless specifically directed by a licensed healthcare provider and consistent with current labeling, semaglutide- or tirzepatide-containing therapies generally should not be combined with other medications in the same class or with other products intended for weight loss without careful clinical review. Patients should also discuss pregnancy plans, contraception, breastfeeding status, any planned surgery or procedure, and the use of oral medications that may be affected by delayed gastric emptying.

Wegovy® tablets

Wegovy® tablets (semaglutide) — sometimes referred to as the “Wegovy® pill” — are FDA-approved prescription medications that may be prescribed when clinically appropriate. They should be used only under the supervision of a licensed healthcare provider and in accordance with the full prescribing information, medication guide, and provider instructions. Wegovy carries a boxed warning regarding the risk of thyroid C-cell tumors. It should not be used in patients with a personal or family history of MTC or in patients with MEN 2.

Additional warnings and precautions may include acute pancreatitis, acute gallbladder disease, hypoglycemia when used with insulin or certain diabetes medications, acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions, hypersensitivity reactions including anaphylaxis and angioedema, diabetic retinopathy complications in certain patients with type 2 diabetes, heart rate increase, and pulmonary aspiration during general anesthesia or deep sedation. Because semaglutide may affect gastric emptying, it may also affect the absorption of certain oral medications. Patients should review the full manufacturer labeling and discuss risks, contraindications, medication timing, and side effects with their provider.

Wegovy Injection

Wegovy injection (semaglutide) is an FDA-approved prescription medication that may be prescribed when clinically appropriate. It carries a boxed warning regarding the risk of thyroid C-cell tumors and should not be used in patients with MTC, MEN 2, or in other situations where the prescribing information or treating provider indicates it is not appropriate.

Warnings and precautions may include acute pancreatitis, acute gallbladder disease, hypoglycemia when used with insulin or insulin secretagogues, acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions, hypersensitivity reactions, diabetic retinopathy complications in certain patients, heart rate increase, and pulmonary aspiration during general anesthesia or deep sedation. Patients should use Wegovy injection only as prescribed and should carefully follow all instructions for dosing, titration, administration, storage, and handling.

Ozempic®

Ozempic (semaglutide) is an FDA-approved prescription medication that may be prescribed when clinically appropriate and consistent with applicable prescribing standards. Ozempic carries a boxed warning regarding the risk of thyroid C-cell tumors and should not be used in patients with a personal or family history of MTC or in patients with MEN 2.

Important risks and warnings may include gastrointestinal adverse reactions, dehydration, acute kidney injury, acute gallbladder disease, pancreatitis, low blood sugar when used with insulin or sulfonylureas, worsening diabetic retinopathy in certain patients, delayed gastric emptying that may affect oral medications, and serious hypersensitivity reactions including anaphylaxis and angioedema. Patients should consult the full prescribing information and medication guide and should promptly contact their provider if serious or persistent symptoms occur.

Zepbound®

Zepbound (tirzepatide) is an FDA-approved prescription medication that may be prescribed when clinically appropriate. Zepbound carries a boxed warning regarding the risk of thyroid C-cell tumors and should not be used in patients with a personal or family history of MTC or in patients with MEN 2.

Important risks and precautions may include severe gastrointestinal side effects, dehydration, kidney problems, gallbladder disease, pancreatitis, serious allergic reactions, low blood sugar when used with insulin or insulin secretagogues, changes in vision in patients with type 2 diabetes, and mood-related symptoms including depression or suicidal thoughts in certain circumstances. Tirzepatide may also affect the absorption or effectiveness of some medications, including oral hormonal contraceptives in some situations. Patients should review full labeling and discuss all concurrent medications and medical conditions with their provider.

Mounjaro®

Mounjaro (tirzepatide) is an FDA-approved prescription medication that may be prescribed when clinically appropriate. Mounjaro carries a boxed warning regarding the risk of thyroid C-cell tumors and should not be used in patients with a personal or family history of MTC or in patients with MEN 2.

Important warnings and precautions may include severe gastrointestinal side effects, dehydration, kidney injury, gallbladder disease, pancreatitis, low blood sugar when used with insulin or sulfonylureas, serious hypersensitivity reactions, severe gastrointestinal disease concerns in some patients, and other adverse effects described in the prescribing information. Patients should use Mounjaro only under provider supervision and should review all manufacturer-provided labeling, instructions for use, and medication guidance.

Compounded Semaglutide

Compounded semaglutide is not reviewed or approved by the FDA for safety, effectiveness, or quality. If compounded semaglutide is prescribed, it is prescribed at the independent clinical judgment of the licensed healthcare provider and dispensed by a licensed pharmacy in accordance with applicable law and pharmacy practice requirements. FDA-approved semaglutide products may be available.

Compounded semaglutide may carry risks similar to other semaglutide-containing therapies, including nausea, vomiting, diarrhea, constipation, abdominal pain, dehydration, delayed gastric emptying, kidney injury, gallbladder problems, pancreatitis, low blood sugar when used with certain diabetes medications, diabetic retinopathy complications in certain patients, and serious hypersensitivity reactions. Patients should understand that compounded medications may differ from branded or FDA-approved products in concentration, excipients, dosage form, administration method, packaging, and storage requirements. Patients should promptly contact their provider if they experience severe, persistent, or concerning symptoms.

Compounded Tirzepatide

Compounded tirzepatide is not reviewed or approved by the FDA for safety, effectiveness, or quality. If compounded tirzepatide is prescribed, it is prescribed at the independent clinical judgment of the licensed healthcare provider and dispensed by a licensed pharmacy in accordance with applicable law and pharmacy practice requirements. FDA-approved tirzepatide products may be available.

Compounded tirzepatide may carry risks similar to other tirzepatide-containing therapies, including nausea, vomiting, diarrhea, constipation, abdominal pain, dehydration, kidney problems, gallbladder disease, pancreatitis, low blood sugar when used with insulin or insulin secretagogues, serious allergic reactions, and possible medication interaction concerns, including with oral contraceptives in certain cases. Patients should review all pharmacy-specific instructions and ask their provider or pharmacist about formulation-specific storage, administration, timing, and side effect expectations.

GLP-1 Microdose (low-dose semaglutide)

“GLP-1 Microdose” or “low-dose semaglutide” refers to a lower-dose treatment approach involving semaglutide that may be considered by a licensed healthcare provider for certain patients. It is not a separate FDA-approved drug product name. If such treatment is provided through a compounded or customized formulation, it is not reviewed or approved by the FDA for safety, effectiveness, or quality.

Even at lower doses, semaglutide-containing therapies may carry meaningful risks and are not appropriate for all patients. Potential risks may include gastrointestinal side effects, dehydration, kidney injury, gallbladder problems, pancreatitis, delayed gastric emptying, low blood sugar when used with certain diabetes medications, and serious allergic reactions. Patients should not assume that a lower dose eliminates the need for clinical oversight, screening, titration, monitoring, or adherence to provider instructions.

Pregnancy, Breastfeeding, and Reproductive Considerations

Patients who are pregnant, planning to become pregnant, or breastfeeding should discuss this with their provider before starting any treatment referenced on this page. Certain semaglutide- and tirzepatide-containing products may not be appropriate during pregnancy or breastfeeding, and treatment may need to be stopped in advance of a planned pregnancy. Patients using oral contraceptives or other time-sensitive oral medications should discuss potential absorption or efficacy considerations with their provider.

Drug Interactions and Medical History Disclosure

Before starting treatment, patients should disclose all relevant medical history and all medications, vitamins, supplements, and herbal products they use. This includes diabetes medications, insulin, sulfonylureas, thyroid medications, anticoagulants, oral contraceptives, and any other prescription or over-the-counter products. Certain GLP-1-related therapies may affect gastric emptying and medication absorption, and combination use with some diabetes therapies may increase the risk of hypoglycemia.

No Guarantee of Results

Individual response to treatment varies. Not all patients will experience the same outcomes, side effects, tolerability, or speed of response. Any examples, testimonials, or descriptions of results are not guarantees of future outcomes. Clinical appropriateness, adherence, follow-up, diet, exercise, coexisting conditions, medication availability, and many other variables may affect results.

Trademarks

Wegovy® and Ozempic® are trademarks of Novo Nordisk A/S. Zepbound® and Mounjaro® are trademarks of Eli Lilly and Company. Better Health Labs, Inc. d/b/a Measured is not affiliated with, endorsed by, or sponsored by the owners of these marks unless expressly stated otherwise.

Questions

For questions about Measured’s services, patients may contact careteam@trymeasured.com. For questions about a prescribed medication, side effects, administration, storage, or whether a treatment remains appropriate, patients should contact their prescribing provider and dispensing pharmacy.